PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Thymidine kinase 1 expression in ovarian serous adenocarcinoma is superior to Ki-67: A new prognostic biomarker.

Abstract Cancer is a disease with abnormally proliferating cells and therefore proliferation rate is an important index for assessing tumour growth. Ki-67 is a commonly used proliferation marker considered to be an unfavourable prognostic marker in some tumors, while Thymidine kinase 1 (TK1) is an interesting proliferation marker because its levels are highly dependent on the growth stage of cells. To define the immunohistochemistry (IHC) expression of the TK1 in patients with ovarian serous adenocarcinoma and establish its potential role as a new biomarker for progressive disease, we analyzed the expression patterns of TK1 and Ki-67 in 109 patients with ovarian serous adenocarcinoma. TK1 and Ki-67 expression both showed a statistically significant correlation to MD Anderson Cancer Center (MDACC) grade, but not to age, tumour size, lymph node metastasis or pathological TNM (pTNM) stages. TK1 expression, MDACC grades, pathological stages and lymph node metastasis correlate to relapse incident rate and overall survival, but Ki-67 does not. Although TK1 expression, MDACC grade, pTNM stage and lymph node metastasis significantly correlate to relapse in the Cox univariate analysis, in the multivariate Cox analysis only TK1 expression and lymph node metastasis were independent prognostic factors. The overall survival also correlated significantly to TK1 expression, MDACC grade, pTNM stage and lymph node metastasis in the Cox univariate analysis. However, only the pTNM stage was found to be an independent prognostic factor for survival in the Cox multivariate analysis. Therefore, though TK1 expression was an independent prognostic factor for relapse, but not for survival, TK1 is a more informative expression than Ki-67 for LI, relapse and overall survival rates. Thus, when TK1 is combined with MDACC grading, pTNM staging and lymph node metastasis, IHC determination of TK1 expression may improve the overall prediction of prognosis in patients with ovarian cancer.
PMID
Related Publications

Expression of cell proliferating genes in patients with non-small cell lung cancer by immunohistochemistry and cDNA profiling.

Muscle-invasive bladder cancer is characterized by overexpression of thymidine kinase 1.

High thymidine kinase 1 (TK1) expression is a predictor of poor survival in patients with pT1 of lung adenocarcinoma.

Thymidine kinase 1 is a better prognostic marker than Ki-67 for pT1 adenocarcinoma of the lung.

Nuclear TK1 expression is an independent prognostic factor for survival in pre-malignant and malignant lesions of the cervix.

Authors

Mayor MeshTerms
Keywords

Ki-67

Ovarian serous adenocarcinoma

prognosis

recurrence

survival

thymidine kinase 1

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28651488
OWN - NLM
STAT- MEDLINE
DA  - 20170627
DCOM- 20170710
LR  - 20170713
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 6
DP  - 2017 Jun
TI  - Thymidine kinase 1 expression in ovarian serous adenocarcinoma is superior to
      Ki-67: A new prognostic biomarker.
PG  - 1010428317706479
LID - 10.1177/1010428317706479 [doi]
AB  - Cancer is a disease with abnormally proliferating cells and therefore
      proliferation rate is an important index for assessing tumour growth. Ki-67 is a 
      commonly used proliferation marker considered to be an unfavourable prognostic
      marker in some tumors, while Thymidine kinase 1 (TK1) is an interesting
      proliferation marker because its levels are highly dependent on the growth stage 
      of cells. To define the immunohistochemistry (IHC) expression of the TK1 in
      patients with ovarian serous adenocarcinoma and establish its potential role as a
      new biomarker for progressive disease, we analyzed the expression patterns of TK1
      and Ki-67 in 109 patients with ovarian serous adenocarcinoma. TK1 and Ki-67
      expression both showed a statistically significant correlation to MD Anderson
      Cancer Center (MDACC) grade, but not to age, tumour size, lymph node metastasis
      or pathological TNM (pTNM) stages. TK1 expression, MDACC grades, pathological
      stages and lymph node metastasis correlate to relapse incident rate and overall
      survival, but Ki-67 does not. Although TK1 expression, MDACC grade, pTNM stage
      and lymph node metastasis significantly correlate to relapse in the Cox
      univariate analysis, in the multivariate Cox analysis only TK1 expression and
      lymph node metastasis were independent prognostic factors. The overall survival
      also correlated significantly to TK1 expression, MDACC grade, pTNM stage and
      lymph node metastasis in the Cox univariate analysis. However, only the pTNM
      stage was found to be an independent prognostic factor for survival in the Cox
      multivariate analysis. Therefore, though TK1 expression was an independent
      prognostic factor for relapse, but not for survival, TK1 is a more informative
      expression than Ki-67 for LI, relapse and overall survival rates. Thus, when TK1 
      is combined with MDACC grading, pTNM staging and lymph node metastasis, IHC
      determination of TK1 expression may improve the overall prediction of prognosis
      in patients with ovarian cancer.
FAU - Wang, Jianjun
AU  - Wang J
AD  - 1 Department of Pathology, Jinling Hospital, Medical School of Nanjing
      University, Nanjing, China.
FAU - Liu, Qi
AU  - Liu Q
AD  - 2 Department of Gynaecology, Jinling Hospital, Medical School of Nanjing
      University, Nanjing, China.
FAU - Zhou, Xiaodie
AU  - Zhou X
AD  - 1 Department of Pathology, Jinling Hospital, Medical School of Nanjing
      University, Nanjing, China.
FAU - He, Yan
AU  - He Y
AD  - 1 Department of Pathology, Jinling Hospital, Medical School of Nanjing
      University, Nanjing, China.
FAU - Guo, Qing
AU  - Guo Q
AD  - 1 Department of Pathology, Jinling Hospital, Medical School of Nanjing
      University, Nanjing, China.
FAU - Shi, Qunli
AU  - Shi Q
AD  - 1 Department of Pathology, Jinling Hospital, Medical School of Nanjing
      University, Nanjing, China.
FAU - Eriksson, Staffan
AU  - Eriksson S
AD  - 3 Department of Anatomy, Physiology and Biochemistry, Faculty of Veterinary
      Medicine and Animal Science, Swedish University of Agricultural Sciences,
      Uppsala, Sweden.
FAU - Zhou, Ji
AU  - Zhou J
AD  - 4 Sino-Swed Molecular Bio-Medicine Research Institute, Shanghai, China.
FAU - He, Ellen
AU  - He E
AD  - 4 Sino-Swed Molecular Bio-Medicine Research Institute, Shanghai, China.
FAU - Skog, Sven
AU  - Skog S
AD  - 4 Sino-Swed Molecular Bio-Medicine Research Institute, Shanghai, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Ki-67 Antigen)
RN  - EC 2.7.1.21 (Thymidine Kinase)
RN  - EC 2.7.1.21 (thymidine kinase 1)
SB  - IM
MH  - Adenocarcinoma/*genetics/pathology
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*biosynthesis/genetics
MH  - Cell Proliferation/genetics
MH  - Disease-Free Survival
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Ki-67 Antigen/biosynthesis/*genetics
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Ovarian Neoplasms/*genetics/pathology
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Thymidine Kinase/*biosynthesis/genetics
OTO - NOTNLM
OT  - Ki-67
OT  - Ovarian serous adenocarcinoma
OT  - prognosis
OT  - recurrence
OT  - survival
OT  - thymidine kinase 1
EDAT- 2017/06/28 06:00
MHDA- 2017/07/14 06:00
CRDT- 2017/06/28 06:00
AID - 10.1177/1010428317706479 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Jun;39(6):1010428317706479. doi: 10.1177/1010428317706479.